President Trump has made American reindustrialization and reshoring central to his economic policy agenda. Reviving American manufacturing enjoys broad public support and has increasingly become a bipartisan priority.
CPA’s submission, “Ensuring U.S. Sovereignty in North American Trade,” concludes that the current trilateral USMCA framework binds two vastly different economies to one unenforceable system—with each reliant on the far larger U.S. consumer market.
The report, titled “Section 232 Steel Tariffs are Necessary for National Security,” highlights how the Trump administration’s Section 232 tariffs have revitalized American manufacturing, created jobs, and strengthened national security.
Witnesses at a Senate hearing on Wednesday, Oct. 29 titled “The Future of Biotech” discussed ways to facilitate reshoring and making it attractive to expand in the U.S. and conduct R&D here instead of in China.
President Trump has already made the most important deal of his life—his promise to the American people to end U.S. dependence on China and rebuild our domestic industrial capacity.
The report, titled “America’s Chip-for-Chip Tariff Policy: The Urgent Fight to Reclaim Industrial Independence Before It’s Too Late,” finds that the United States now produces only 10 percent of the world’s chips—and almost none of the most advanced ones—while China has captured the majority of global capacity for legacy chips, the mature semiconductors essential to cars, medical devices, and industrial equipment.
On the surface, America looks like an unrivaled success story. Yet beneath the headline numbers lies an economy increasingly dependent on foreign production, hollowed out in critical industries, and unable to provide secure, high-wage work for many of its citizens.
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
The Trump administration’s section 232 investigation into medical devices and personal protective equipment is a vital step toward ensuring America takes back control over its production and domestic supply of critical medical products.
The hearing continued the committee’s efforts to examine and reduce America’s severely dangerous over-dependence on foreign-manufactured generic drugs and address vulnerabilities in the nation’s pharmaceutical supply chain.
